SMMT stock forecast, quote, news & analysis
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases... Show more
Why Summit Therapeutics Inc. (SMMT) Is Up +57% in the Last 30 Days
Key Takeaways
- SMMT stock surged 57% over the past 30 days, driven by positive Phase III data for ivonescimab and U.S. FDA acceptance of its Biologics License Application (BLA).
- Over the past quarter, shares rose 43%, reflecting steady clinical progress amid biotech sector volatility.
- Key catalysts include ivonescimab trial results in non-small cell lung cancer (NSCLC) patients and upcoming conference presentations.
- Negative beta (-1.37) highlights inverse market correlation, aiding performance during broader pullbacks.
- Market sentiment boosted by oncology pipeline advancements in a competitive immunotherapy landscape.
Summit Therapeutics Inc. (SMMT) Company Overview and Market Position
Summit Therapeutics Inc. is a biopharmaceutical company specializing in oncology, focused on discovering, developing, and commercializing therapies aimed at improving patient outcomes. Its lead candidate, ivonescimab—a bispecific antibody combining PD-1 blockade and anti-angiogenesis—targets non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company operates in a crowded immuno-oncology field, competing with established players through differentiated combination therapies paired with chemotherapy in Phase III trials. Strong clinical momentum has underpinned recent stock price movement, as positive data validates its pipeline against serious unmet needs in advanced cancers.
Summit Therapeutics Inc. (SMMT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, SMMT stock climbed from $15.60 on March 18, 2026, to $24.42 on April 16, 2026, marking a +57% gain. The move was trend-driven with heightened volatility, accelerating sharply in early April amid clinical news.
For the quarter, shares advanced +43% from $17.04 on January 16, 2026, to the recent $24.42 close. Performance featured dips in February and early March before a robust recovery, exhibiting range-bound behavior initially then breaking higher on catalysts.
What Drove SMMT Stock Price in the Last 30 Days
The 57% rally stemmed primarily from ivonescimab milestones. New Phase III data showcased efficacy in advanced NSCLC populations, including HARMONi trial updates on progression-free survival (PFS), sparking investor enthusiasm. The U.S. FDA's acceptance of the BLA for ivonescimab combined with chemotherapy further fueled gains, signaling potential approval pathways for first-line metastatic NSCLC. Analyst coverage highlighted valuation upside post-data, with shares jumping 6.9% on filing news alone. Positive sentiment in biotech, tied to oncology breakthroughs, amplified the uptrend despite broader market fluctuations.
What Drove SMMT Stock Performance Over the Last Quarter
The quarter's 43% advance reflected sustained ivonescimab progress amid oncology sector tailwinds. Early dips followed Q4 2025 financials showing wider losses, but recovery built on Phase III readouts and conference previews like ELCC 2026 data presentations on March 27. Macro factors, including interest rate stability supporting growth stocks, aided rebound. Institutional interest grew with pipeline validation, outweighing competitive pressures in PD-1 inhibitors. Cumulative clinical catalysts overshadowed interim volatility, driving net gains.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots amid hundreds available across thousands of tickers. These curated bots employ diverse strategies—such as trend-following, mean reversion, or momentum—across various timeframes like intraday, swing, or long-term holds. Performance metrics highlight win rates, average returns, and drawdowns, helping traders identify relevant tools for stocks like SMMT. Updated in real-time, the section filters for consistency and relevance, offering transparency via backtested and live results. Explore these bots to enhance your stock analysis and automate market trends trading.
SMMT Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor FDA review timelines for the ivonescimab BLA, including potential advisory committee meetings. Upcoming earnings could detail trial expenses and cash runway. Conference presentations, like ELCC follow-ups, may reveal additional NSCLC or CRC data. Broader oncology trends, regulatory shifts, and macroeconomic influences on biotech funding remain key. Risks include trial delays or competitive readouts; catalysts like partnerships could sway sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Momentum Indicator for SMMT turns negative, indicating new downward trend
SMMT saw its Momentum Indicator move below the 0 level on May 22, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 104 similar instances where the indicator turned negative. In of the 104 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for SMMT turned negative on June 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
SMMT moved below its 50-day moving average on May 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SMMT crossed bearishly below the 50-day moving average on May 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMMT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SMMT entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SMMT's RSI Indicator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for SMMT moved above the 200-day moving average on May 27, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SMMT advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .
SMMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SMMT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.920) is normal, around the industry mean (18.720). P/E Ratio (26.355) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.682). SMMT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (357.550).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel medicines
Industry Biotechnology